Request for Proposals-Leukemia and Lymphoma/Myeloma

The Leukemia & Lymphoma Society (LLS) Will Continue to Highlight Areas of Unmet Medical Need within the Translational Research Program

The LLS Translational Research Program was created in 1995 with the goal of accelerating clinical applications of laboratory findings relevant to improved diagnosis and management of leukemia, lymphoma, myeloma and other hematopoietic malignancies. In particular, the LLS Research staff and Medical and Scientific Affairs Committee encourage the submission of research proposals that are designed to accomplish one of the following:

1. **Personalized medicine approach for cancer treatment.** Advances in cancer care have significantly improved lives of patients with hematologic diseases such as CLL, CML, Hodgkin Lymphomas, and ALL. LLS believes that, with time, complete cures can be achieved for certain diseases or subtypes of diseases. Therefore, LLS will continue to support research that may revolutionize cancer care for any hematologic disease through the use of state of the art technologies for molecular profiling, early disease detection, prognostic/predictive biomarkers, development of liquid biopsy technology and novel target identification, and patient selection.

2. **Development of novel therapies and/or novel therapeutic strategies including those that target mutational and epigenetic events within the microenvironment.** LLS is especially interested in novel immunotherapy approaches. Such therapies can be applicable to any hematologic malignancies but emphasis is warranted in the following areas:
   a. Aggressive subtypes of Non-Hodgkin Lymphoma including but not limited to DLBCL, tFL, PTCL, and ALCL
   b. Indolent lymphoma including but not limited to CLL, FL, WM (therapies with the potential to provide significant extension of lives of patients or total disease control in defined subtypes)
   c. Myeloid disorders including MPN/MDS/AML as well as lymphoid disorders such as ALL
   d. Multiple Myeloma and pre-emergent conditions

3. **Improvements of safety and efficacy of stem cell transplantation.**
4. Long-term outcome assessment following therapies.

5. Progress in understanding neoplastic stem cell growth and differentiation as well as cancer cell/microenvironmental interactions especially with translation to novel therapies.

6. While significant progress has been made against some of the pediatric diseases, LLS recognizes and calls for proposals designed to advance therapies in pediatric indications with novel approaches or to minimize therapy-related effects of existing treatments.

A detailed description of the LLS Translational Research Program and application instructions are available at lls.fluxx.io or www.lls.org under the Research tab. All applications are to be submitted online through FLUXX at lls.fluxx.io. Applicants with research proposals that are responsive to the RFP should indicate this on the title page of their Full Proposal. The LLS seeks proposals responsive to the above requests for proposals but will also consider other exceptional proposals with the near-term potential of clinical translation.

For additional questions regarding LLS grant programs, eligibility, and application processes, please contact researchprograms@lls.org.